^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

    Excerpt:
    We randomly assigned 463 patients with 1% or more EGFR tumor cell membrane staining...Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Median PFS time was 8 weeks (95% CI, 7.9 to 8.4) for panitumumab and 7.3 weeks (95% CI, 7.1 to 7.7) for BSC. Mean (standard error) PFS time was 13.8 (0.8) weeks for panitumumab and 8.5 (0.5) weeks for BSC.
    DOI:
    10.1200/JCO.2006.08.1620
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

    Excerpt:
    ...- Paraffin-embedded tumor tissue available for immunohistochemistry studies of epidermal growth factor receptor (EGFr) expression (archived tissue is acceptable)...
    Trial ID:
    NCT00111761
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

    Excerpt:
    ...- Paraffin-embedded tumor tissue available for immunohistochemistry (IHC) studies of epidermal growth factor receptor (EGFr) expression (archived tissue is acceptable)...
    Trial ID:
    NCT00111774
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

    Excerpt:
    ...DISEASE CHARACTERISTICS: - Histologically confirmed colorectal cancer - Metastatic disease - Must have been free of disease for at least 1 year if received prior adjuvant fluorouracil - Epidermal growth factor receptor (EGFR) over-expression by immunochemistry (staining 2+ or 3+ in at least 10% of tumor cells) - Unidimensionally measurable disease - - PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin - AST and ALT - Creatinine - LVEF at least 45% by MUGA - - HIV negative - - Negative pregnancy test - Fertile patients must use effective contraception during and for 1 month after study participation - - PRIOR CONCURRENT THERAPY: Biologic therapy - - See Disease Characteristics - - - - Prior surgery for colorectal cancer allowed Other - At least 30 days since prior investigational drugs - - - - - - - - ...
    Trial ID:
    NCT00047151
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

    Excerpt:
    ...- Tumor expressing epidermal growth factor receptor (EGFr) by immunohistochemistry...
    Trial ID:
    NCT00113763
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients

    Excerpt:
    ...- Immunohistochemical evidence of EGFR expression....
    Trial ID:
    NCT02139215
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients

    Excerpt:
    ...- Immunohistochemical evidence of EGFR expression....
    Trial ID:
    NCT02135757
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

    Excerpt:
    ...- Tumor expressing epidermal growth factor receptor (EGFr) by immunohistochemistry...
    Trial ID:
    NCT00083616
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

    Excerpt:
    ...- Tumor expressing EGFr levels by immunohistochemistry (membrane staining must be positive in 1% of evaluated tumor cells)....
    Trial ID:
    NCT00327119